Qiagen to acquire Parse Biosciences for up to $280M

Qiagen (QGEN) announced it has entered into a definitive agreement to fully acquire Parse Biosciences, a provider of scalable, instrument-free solutions for single-cell research. “The acquisition will significantly expand Qiagen’s Sample technologies portfolio into the fast-growing single-cell sequencing market with highly scalable chemistry designed to power research involving up to millions and billions of cells. Parse’s scalable chemistry is also expected to accelerate growth in the Qiagen Digital Insights bioinformatics business, enabling customers to generate, process and interpret AI-driven single-cell data more efficiently and at much greater scale, from the first sample to actionable insights,” the company stated. Qiagen will fully acquire Parse Biosciences for an upfront payment of approximately $225M in cash, with Parse equityholders eligible for additional milestone payments of up to $55M based on the achievement of targets over a multi-year period. The transaction, which is subject to clearance under the U.S. Hart-Scott-Rodino Antitrust Improvements Act and other customary conditions, is expected to be completed in December 2025 and not provide any meaningful contributions for the year. For full-year 2026, Parse is expected to contribute approximately $40M in sales to Qiagen, or approximately two percentage points of growth, with sales expected to increase at a strong double-digit rate in subsequent years. The transaction is expected to be dilutive to adjusted earnings per share by approximately 4c in 2026 and accretive beginning in 2028.